In accordance with this result, AIM−/− CD1 mice, which were newly created using the CRISPR/Cas9 strategy, exhibited worse survival predominantly during the acute phase (days 2 and 3) than wild-type CD1 mice in response to IR plus HS, whereas the difference in AIM−/− CD1 mice under IR with or without HS was less significant, clearly indicating the involvement of AIM in the difference in AKI severity between HS-IR and IR mice (Fig 3C). This evidence concerns the gene CD5L and acute kidney injury.